electroCore Reports Q2 2026 Net Sales of $9.5 Million
electroCore recorded a 28% year-over-year increase in net sales to $9.5 million for Q2 2026. The bioelectronic company also increased its full-year 2026 revenue outlook to over 30% growth, boosted by strong prescription growth in the VA and the Truvaga product line.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day